Trial Profile
Genotype-Driven Treatment of Advanced Non-Small Cell Lung Cancer Based on mRNA Expression of ERCC1 and RRM1 as First-Line Chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Carboplatin; Gemcitabine; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 04 Mar 2014 According to ClinicalTrials.gov record planned end date changed from 1 Jul 2015 to 1 Feb 2015.
- 04 Mar 2014 According to ClinicalTrials.gov record planned end date changed from 1 Jul 2015 to 1 Feb 2015.
- 26 Jul 2012 Planned number of patients changed from 117 to 162 as reported by ClinicalTrials.gov (NCT01648517).